US FDA Grants Fast Track Designation for Paradigm's Phase 3

US FDA Grants Fast Track Designation for Paradigm’s Phase 3 Osteoarthritis ProgramFDA Fast Track Designation for Pentosan Polysulfate Sodium (Zilosul™/PPS) offers pathways to expedite development of Paradigm’s osteoarthritis clinicalFDA Fast Track acknowledges osteoarthritis as a serious disease wi...

Related Keywords

Canada , Australia , Melbourne , Victoria , United Kingdom , Donna Skerrett , University Of Accessed , Institute For Health , Paradigm Biopharmaceuticals Ltd , Paradigm Biopharmaceuticals , Osteoarthritis Program , Drug Administration , Global Health Data Exchange , Fast Track Designation , Track Designation , Pentosan Polysulfate Sodium , Biopharmaceuticals Ltd , Paradigm Chief Medical Officer , Health Data Exchange , Metrics Evaluation , Accessed June , Serious Disease , Drug Administration December , Patient Global Impression ,